<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03089138</url>
  </required_header>
  <id_info>
    <org_study_id>regan tangjiang phase 2</org_study_id>
    <nct_id>NCT03089138</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Regan Tangjiang for Treating the Common Cold With Wind-heat Syndrome</brief_title>
  <official_title>Efficacy and Safety of Regan Tangjiang for Treating the Common Cold With Wind-heat Syndrome: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo and Active-Controlled Phase 2b Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Da-an Bio-technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Da-an Bio-technology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and Safety of Regan Tangjiang for treating the common cold with wind-heat syndrome:
      A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo and Active-Controlled Phase
      2b Study
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2017</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to fever relief</measure>
    <time_frame>day 1 to day 3</time_frame>
    <description>The median time from the first dosing to time when the body temperature drops by at least 0.5℃.In this study, all patients will be required to record their body temperature in the patient diary every 2 hours within the first 12 hours and every 4 hours during the following 12 hours. After that, it should be recorded four times at a fixed time every day.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to fever clearance</measure>
    <time_frame>day 1 to day 3</time_frame>
    <description>The median time from the first dose administration to the time when the body temperature drops below 37.3℃ and lasts for 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to symptom disappearance</measure>
    <time_frame>day 1 to day 3</time_frame>
    <description>The median time from study enrollment to the time when each individual symptom （such as fever, pharyngalgia, headache, runny nose, blocked nose, sneezing, cough） completely disappear.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disappearance rate of symptoms</measure>
    <time_frame>day 1 to day 3</time_frame>
    <description>The percentage of patients with each individual symptom completely disappear from study enrollment to three days treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy in TCM symptom and sign scores</measure>
    <time_frame>day 1 to day 3</time_frame>
    <description>The TCM symptom scoring system used in the study follows the Guidelines for Clinical Research of New Chinese Medicine, in which all symptoms are graded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usage of emergency medicines</measure>
    <time_frame>day 1 to day 3</time_frame>
    <description>Usage of emergency medicines is defined as the percentage of patients using emergency medicines (paracetamol).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cold</condition>
  <arm_group>
    <arm_group_label>Regan Tangjiang，Simulation Shufengjiere Capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Simulation Regan Tangjiang，Shufengjiere Capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Simulation Regan Tangjiang and Shufengjiere Capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regan Tangjiang</intervention_name>
    <description>The treatment duration is 3 consecutive days.</description>
    <arm_group_label>Regan Tangjiang，Simulation Shufengjiere Capsules</arm_group_label>
    <arm_group_label>Simulation Regan Tangjiang，Shufengjiere Capsules</arm_group_label>
    <arm_group_label>Simulation Regan Tangjiang and Shufengjiere Capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of common cold according to Western Medicine，with symptoms onset and fever
             less than 24 hours prior to randomization；

          -  After the onset of the disease, with the following symptoms: sore throat and axillary
             temperature between 38.5 and 38.9°C inclusive.

          -  Diagnosis of wind-heat syndrome according to TCM；

          -  Aged between 18 to 65 years；

          -  Willingness to participate and to sign the informed consent form.

        Exclusion Criteria:

          -  Participants with Pneumonia, suppurative tonsillitis, acute tracheobronchitis, acute
             and chronic sinusitis, pulmonary tuberculosis and other diseases;

          -  White blood cell count &gt;11.0×109/L, or neutrophil percentage&gt;75%;

          -  Participants with liver function 1.5 times higher than the normal upper limit or serum
             creatinine higher than the normal upper limit;

          -  Participants with severe primary diseases of cardiovascular, brain, lung, liver,
             kidney and hematopoietic system , such as viral hepatitis, hemophilia, diabetes,
             psychosis and so on;

          -  Participants who had used other drugs to treat common cold after the onset of the
             disease, including antivirals, antibiotics and traditional Chinese medicine.

          -  Women who are pregnant or breast-feeding;

          -  Allergic condition (refer to history of allergy to two or more drugs or food) or
             allergy to the drug composition(s);

          -  Participation in another clinical study of an investigational drug within 3 months

          -  Participants who are not suitable for the trial decided by the researchers for any
             reason, such as pregnancy, frequently changes in work or living environments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2017</study_first_submitted>
  <study_first_submitted_qc>March 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2017</study_first_posted>
  <last_update_submitted>March 19, 2017</last_update_submitted>
  <last_update_submitted_qc>March 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Common Cold</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

